EUCTR2012-001142-18-NL进行中（未招募）不适用
Efficacy and pharmacokinetics of a switch from a regimen consisting of emtricitabine, nevirapine and tenofovir to rilpivirine, emtricitabine and tenofovir in virologically suppressed HIV-1 infected patients. - rilpivirine switch study
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Erasmus MC
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Able to take medication with a 500 kcal meal.
- •Treated with NVP, FTC, TDF for at least the last 9 months.
- •No history of HIV virologic failure.
- •The last 2 measured HIV-RNA levels in plasma were <50 copies/ml.
- •=6 months between the first and last plasma with <50 copies/ HIV RNA/ml.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of proton pump inhibitors.
- •Use of H2-antagonists.
研究者
相似试验
尚未招募
不适用
Efficacy and pharmacokinetics of a switch from a regimen consisting of emtricitabine, nevirapine and tenofovir to rilpivirine, emtricitabine and tenofovir in virologically suppressed HIV-1 infected patients.HIVNL-OMON26054Erasmus MC50
已完成
不适用
Study for efficacy and safety of switching treatment from ENBREL to etanercept biosimilarRheumatoid arthritisJPRN-UMIN000032633Matsubara Mayflower Hospital200
进行中（未招募）
不适用
Farmacokinetische evaluatie van de overschakeling van intraveneuze naar enterale toediening van moxifloxacine bij Intensieve Zorgen patiënteEUCTR2006-006334-18-BEniversity Hospital Gent
招募中
不适用
Investigation of the usefulness of drug change from one type to another type of 5-ASA (5-mesalamine) in the treatment of ulcerative colitis during the relapse statelcerative colitisJPRN-UMIN000010544GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE40
已完成
不适用
The evaluation of the efficacy of a switch from GnRH agonist to GnRH antagonist in prostate cancer patients who relapsed during combined androgen blockade.prostate cancerJPRN-UMIN000013514Tokai Urological Clinical Trial Group50